Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
G1 Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GTHX
Nasdaq
8731
https://www.g1therapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for G1 Therapeutics Inc
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 1st, 2024 9:20 pm
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 3:21 pm
Q4 2023 G1 Therapeutics Inc Earnings Call
- Feb 29th, 2024 4:09 am
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
- Feb 28th, 2024 12:40 pm
G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023
- Feb 28th, 2024 11:51 am
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Feb 28th, 2024 11:30 am
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 1:30 pm
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutions
- Feb 17th, 2024 1:47 pm
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
- Feb 15th, 2024 1:30 pm
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- Feb 12th, 2024 9:05 pm
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2024 11:45 am
Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc
- Jan 3rd, 2024 10:02 pm
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 2:00 pm
Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics Inc
- Dec 14th, 2023 4:05 am
G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%
- Dec 8th, 2023 10:18 am
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
- Dec 5th, 2023 2:26 pm
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
- Nov 30th, 2023 1:37 am
When Will G1 Therapeutics, Inc. (NASDAQ:GTHX) Turn A Profit?
- Nov 11th, 2023 2:00 pm
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript
- Nov 2nd, 2023 1:46 pm
Q3 2023 G1 Therapeutics Inc Earnings Call
- Nov 2nd, 2023 3:49 am
Scroll